What is the recommended dose of cryoprecipitate per kilogram for consumptive intravascular coagulation (CIVD)?

Recommended Dose of Cryoprecipitate for Consumptive Intravascular Coagulation (CIVD)

The recommended initial dose of cryoprecipitate for consumptive intravascular coagulation is 50 mg/kg, which is approximately equivalent to 15-20 single donor units in a 70 kg adult, or approximately 1 unit per 10 kg body weight. 1

Dosing Algorithm

Initial Dose

• 50 mg/kg of cryoprecipitate (Grade 1C recommendation from European trauma guidelines) 1
• This translates to approximately 15-20 units for a 70 kg adult
• Alternative calculation: 1 unit per 10 kg body weight raises fibrinogen by approximately 50 mg/dL 2

Indications for Administration

Administer cryoprecipitate when:

• Fibrinogen level < 1.5-2.0 g/L (150-200 mg/dL) in the presence of significant bleeding 1, 3
• Thromboelastometric signs of functional fibrinogen deficit (e.g., FIBTEM A10 < 9 mm) 4, 3
• In massive transfusion when fibrinogen cannot be measured timely 5

Repeat Dosing

• Guide subsequent doses by:
  • Serial thromboelastometry monitoring (preferred method) 1
  • Laboratory fibrinogen levels (Clauss method, though may overestimate in presence of colloids) 1
  • Target fibrinogen level ≥ 1.5-2.0 g/L 3

Important Clinical Context

Volume and Expected Response

• Each cryoprecipitate unit contains 10-20 mL volume 2
• 1 unit per 10 kg body weight increases fibrinogen by approximately 50 mg/dL 2
• Average dose of 5-10 units (50-200 mL total volume) 2
• In practice, 8.7 units caused mean increase of 0.55 g/L, or approximately 0.06 g/L per unit 6

Timing Considerations

• Fibrinogen is typically the first coagulation factor to critically decrease during massive hemorrhage 1, 4
• Administer within 90 minutes of arrival and within 3 hours of injury for trauma patients 7
• Early administration is crucial as hypofibrinogenemia develops before 10 units of RBCs are transfused 8

Critical Caveats and Pitfalls

Recent Evidence Challenges Empiric Use

The 2024 CRYOSTAT-2 trial (n=1,531 trauma patients) showed no mortality benefit from empiric early cryoprecipitate administration (25.3% vs 26.1% mortality, p=0.74) 7. Importantly:

• There was significant crossover (32% of control group received cryoprecipitate)
• Cryoprecipitate was given empirically without documented hypofibrinogenemia
• Fibrinogen levels at administration were not reported
• This suggests cryoprecipitate should be targeted, not empiric 9

Optimal Ratio in Massive Transfusion

Recent data suggests 1 unit of cryoprecipitate per 7-8 units of RBCs provides optimal survival benefit 10:

• RBC:Cryo ratios ≤8:1 associated with significant survival benefit
• Lower doses (>8:1 ratio) showed no mortality benefit
• This applies when using viscoelastic-guided resuscitation 11

Whole Blood Impact

When incorporating whole blood into resuscitation, cryoprecipitate is needed later in the resuscitation:

• Whole blood resuscitation: cryoprecipitate after 10 units (10:9.5:1.7:1 ratio) 11
• Component-only strategy: cryoprecipitate after 7 units (7:6:1:1 ratio) 11

Monitoring Preference

Thromboelastometry is preferable to laboratory fibrinogen measurement because:

• Provides real-time functional assessment 1
• Laboratory methods have methodological issues 1
• Clauss method significantly overestimates fibrinogen in presence of hydroxyethyl starch 1

Safety Considerations

• Cryoprecipitate is a pooled product without pathogen inactivation 12
• Associated risks include transfusion-related acute lung injury (TRALI) and pathogen transmission 12
• Consider fibrinogen concentrate as alternative where available (3-4 g dose equivalent) 1, 4, 3

Specific to CIVD/DIC

For consumptive coagulopathy specifically:

• Cryoprecipitate corrects consumption of fibrinogen and platelets 13
• Should be part of multimodal approach including treating underlying trigger 13
• Consider when fibrinogen < 80-100 mg/dL with microvascular bleeding 5